---
document_datetime: 2025-10-09 14:25:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gardasil-9-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: gardasil-9-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0377058
conversion_datetime: 2025-12-15 01:11:46.915033
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Gardasil 9

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 09/10/2025                          |                                          | PL                              |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                     | Update of the package leaflet with revised contact details oflocal representative.                                                                                                                                                                                 |            |     |    | EMA/N/0000303460   |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|--------------------|
| Variation typeIA/ EMA/VR/0000278523 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsible do not include batch release - Accepted | 08/08/2025 | N/A |    |                    |
| Article 61(3) /                     | -Notification acc.Article 61(3)-Accepted Updateofthepackageleafletwithrevised contactdetailsoflocalrepresentative and deletion of 'United Kingdom (Northern Ireland)'from thelistoflocal representatives in line with the QRD template v10.4.                      | 15/07/2025 |     | PL | EMA/N/0000284679   |
| Variation type IB /                 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in themanufacturingprocess oftheactivesubstance-Accepted                                                                                                             | 28/05/2025 | N/A |    | EMA/VR/0000268059  |
| Variation type IB /                 | B.II.b.1Replacement or addition of a manufacturingsiteforpartor all ofthe manufacturingprocessofthefinished product - B.1I.b.1.z Change in supplier of sterilisedprimarycontainercomponents,                                                                       | 25/05/2025 | N/A |    | EMA/VR/0000259171  |

<div style=\"page-break-after: always\"></div>

| which are to be used in the aseptic manufacture of medicinal products - Accepted   |
|------------------------------------------------------------------------------------|